Explore the Agenda
7:45 am Check-In & Morning Coffee
9:00 am Program Director’s Opening Remarks
9:05 am Chair’s Opening Remarks
Navigating the Design & Clinical Translation of Costimulatory T-Cell Engagers to Improve Response Rates Whilst Maintaining Safety
9:15 am Optimizing Strategy for 4-1BB Costimulatory Bispecifics to Maximize Anti-Tumor Effects While Managing Historical 4-1BB Safety Challenges
- Exploring BH3120, a bivalent bispecific antibody generated by Pentambody® platform targeting 4-1BB and PD-L1 simultaneously, with monovalent anti-4-1BB arm (moderate affinity) and anti-PD-L1 arm (high affinity)
- Discussing how in preclinical evaluations, BH3120 demonstrated a favorable safety profile with low risk of hepatotoxicity and robust antitumor activity across multiple tumor models, with enhanced activity observed in combination with PD-1 blockade
- Outlining how early clinical results indicate a favorable safety profile by mitigating the risk of hepatotoxicity and providing initial evidence of antitumor activity across a range of tumor types
9:45 am Optimizing T-Cell Engaging Therapies from Preclinical Study to Human Clinical Trials: Conditional Activation of T-Cells in the Tumor Microenvironment by a Novel 4-1BB T-Cell Engaging BsAb (Grabody T)
- Outlining the Grabody T platform, a clinically validated 4-1BB bispecific antibody approach to overcoming liver toxicity
- Unveiling how the targeted activation of Grabody T exhibits TAA-dependent 4-1BB activation and strong in vivo efficacy
- Examining the promising clinical activity and favorable safety profile across the Grabody T pipeline (Givastomig, Ragistomig, and YH32367)
10:15 am Refreshment Break
10:45 am Networking Session
This is your opportunity to have face-to-face conversations with fellow attendees of the World Targeted Therapeutics Summit South Korea by Hanson Wade. Progress your bispecific candidates forward and make connections with global pharma and biotech working on bispecifics, T-cell engagers, ADCs, targeted protein degradation, and induced proximity, as well as, global service providers, in a mix of pre-organized and random networking.
Advancing Multispecific Antibody Design to Deepen Response Rate, Prevent Antigen Escape & Tackle Resistance
11:30 am Engineering Affinity Windows to Balance Potency, Safety & Durability in Bispecifics & T-Cell Engagers
- Designing optimal affinity windows across tumor and CD3 arms to drive effective synapse formation, while avoiding excessive T-cell activation and offtumor toxicity
- Understanding how affinity tuning influences serial killing, T-cell exhaustion, and durability of the response, particularly in solid tumor settings
- Applying affinity engineering strategies early in bispecific and T-cell engager design to improve clinical predictability and reduce downstream safety and development risk
12:00 pm Session Reserved for AdiMab
12:30 pm T‑Cell Redirecting Therapies: Delivering Deeper & Broader Clinical Impact
- Exploring how T‑cell engagers (TcEs) are a powerful next-generation immunotherapy that reprogram “cold” tumors into “hot” tumors by redirecting T-cells toward tumor antigens
- Discussing how Boehringer Ingelheim is advancing a diverse and innovative TcE pipeline, which includes assets such as obrixtamig (DLL3/CD3), supported by cutting-edge antigen discovery platforms to identify tumor-selective targets and expand therapeutic opportunities
- Overcoming solid tumor challenges with integrated strategies that include identifying tumor-specific targets, engineering selective and potent TcE formats, applying smart combinations, and selecting the right patients to maximize clinical benefit and therapeutic window
1:00 pm Lunch
1:45 pm Networking Session
This is your opportunity to have face-to-face conversations with fellow attendees of the World Targeted Therapeutics Summit South Korea by Hanson Wade. Progress your bispecific candidates forward and make connections with global pharma and biotech working on bispecifics, T-cell engagers, ADCs, targeted protein degradation, and induced proximity, as well as, global service providers, in a mix of pre-organized and random networking.
Reducing On-Target, Off-Tumor Toxicity Through Smarter Targeting Strategies & Conditional Activation
2:30 pm T-cube Platform: Enabling Safer & More Effective Next-Generation T-Cell Engagers
- Outlining how T-cube activates T-cells only in the presence of tumor-associated antigens by leveraging CD137, minimizing off-tumor activation, and reducing the risk of systemic toxicity
- Evaluating how, by avoiding direct CD3 engagement, T-cube significantly lowers the risk of cytokine release syndrome while maintaining strong antitumor activity in solid tumors
- Discussing how the modular T-cube architecture supports multiple bispecific programs -AP203, AP402, and AP601- each targeting distinct tumor biology and high-value indications
3:00 pm Novel Tetravalent Bispecific Antibody, PSMA/TRAIL‑R2 REGULGENT™, Induces Selective Tumor Cell Apoptosis Without Hepatotoxicity
- Explore how a novel tetravalent PSMA/TRAIL‑R2 bispecific antibody (REGULGENT™) was engineered to enable potent TRAIL‑R2 clustering while restricting activation to PSMA‑expressing tumor cells
- Discover how the molecule selectively induced apoptosis in PSMA/TRAIL‑R2 double‑positive tumor cells, demonstrating superior activity compared with bivalent bispecific formats
- Discuss comprehensive in vitro and in vivo studies which confirmed that REGULGENT™ achieves tumor‑specific killing without hepatotoxicity, highlighting its potential as a safer TRAIL‑R2‑targeted therapy
3:30 pm Refreshment Break & Poster Session
Contribute to the conversation and showcase your groundbreaking research in bispecific antibodies and T-cell engager drug discovery and development.
4:30 pm Bispecific Antibody Combinations for Optimized Anti-Tumor Activity in Liquid & Solid Tumors
- Co-localizing "signal 1" (TCR) and "signal 2" (co-stimulation) within the tumor microenvironment to drive optimized anti-tumor responses
- Integrating signal 3 (cytokine support) for even deeper anti-tumor responses
- Preclinical and clinical data support rational combinations with biologics in patients
5:00 pm An Overview of the Bispecific Development Landscape in Asia
- Highlighting the preclinical and clinical bispecific landscape in Asia
- Analyzing the commercial landscape, with emphasis on leading companies and key deals
- Examining the future of bispecific development in Asia